Nrx Pharmaceuticals, INC. 8-K/A Filing

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 pershare NRXP The Nasdaq Stock Marke

Filing Documents

• nrxp20251118_8ka.htm (8-K/A) — 38KB
• ex_890964.htm (EX-23.1) — 3KB
• ex_889984.htm (EX-99.1) — 245KB
• ex_889993.htm (EX-99.2) — 230KB
• ex_889994.htm (EX-99.3) — 293KB
• a01.jpg (GRAPHIC) — 12KB
• 0001437749-25-036005.txt ( ) — 1045KB
• nrxp-20250908.xsd (EX-101.SCH) — 4KB
• nrxp-20250908_def.xml (EX-101.DEF) — 14KB
• nrxp-20250908_lab.xml (EX-101.LAB) — 18KB
• nrxp-20250908_pre.xml (EX-101.PRE) — 14KB
• nrxp20251118_8ka_htm.xml (XML) — 5KB

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (a)

Financial statements of business acquired

Financial statements of business acquired. The audited financial statements of Dura Medical as of and for the fiscal year ended December 31, 2024, and the notes related thereto, are filed as Exhibit 99.1 of the Company's Current Report on Form 8-K, and are incorporated by reference into this Item 9.01(a). The unaudited financial statements of Dura Medical as of June 30, 2025 and for the six months ended June 30, 2025, and the notes related thereto, are filed as Exhibit 99.2 of the Company's Current Report on Form 8-K and are incorporated by reference into this Item 9.01(a). (b) Pro forma financial information. The unaudited pro forma combined balance sheet as of June 30, 2025 and the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025 and for the fiscal year ended December 31, 2024, and the notes related thereto, are filed as Exhibit 99.3 of the Company's Current Report on Form 8-K and are incorporated by reference into this Item 9.01(b). (d) Exhibits Exhibit No. Description 23.1 Consent of Weinberg & Company, P.A. (Dura Medical 2024) 99.1 Audited financial statements of Dura Medical, LLC as of December 31, 2024 and for the year ended December 31, 2024, and the notes related thereto 99.2 Unaudited financial statements of Dura Medical, LLC as of June 30, 2025 and for the six months ended June 30, 2025, and the notes related thereto 99.3 Unaudited Pro Forma Combined Financial Statements. 104 Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NRx Pharmaceuticals, Inc. Date: November 21, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Its: Interim Chief Executive Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR